A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Main Authors: | , , , , , , , , , |
---|---|
Format: | Journal article |
Published: |
2011
|